Alsalim W, Lindgren O, Ahrn B (2023) GIP and GLP-1 secretion in humans characteristics and regulation
The STEP clinical trials, particularly at 2.4 mg a week, revealed significant weight loss in both diabetic and non-diabetic populations, with body weight reductions ranging from 10% to 15% over extended periods (6)(23)(39)
10.1016/S0140-6736(15)60936-9 10 BolliG
Attorneys Office described how in a ruse to avoid FDA scrutiny, the peptides had been labeled for research/laboratory use only. Brunner states that the use of such peptides, which come from unknown and possibly unregulated manufacturers, is risky: For a patient to trust and inject that substance into their body is incredibly dangerous. Even when the active ingredient is safe, DIYers open themselves up to other risks when reconstituting their medicine
Thats a smart question to ask and one we hear often
Clinical evidence shows semaglutide can cause small increases in resting heart rate, typically a few beats per minute